Trial Profile
Evaluation of the Effect of 0.4 mg Nitroglycerin Spray After Pretreatment With Multiple Once Daily Oral Doses of 2.5 mg, 5 mg and 10 mg Vericiguat (BAY 1021189) Each Given Over 14 ± 3 Days on Safety, Tolerability and Blood Pressure in a Multi-center, Randomized, Placebo-controlled, Double-blind Group Comparison Study in Stable Coronary Artery Disease (CAD) Patients Aged 30 to 80 Years
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 12 May 2022
Price :
$35
*
At a glance
- Drugs Vericiguat (Primary) ; Nitroglycerin
- Indications Angina pectoris; Coronary artery disease
- Focus Adverse reactions
- Acronyms VENICE
- Sponsors Bayer
- 08 Mar 2022 Results evaluating safety, tolerability, and the pharmacodynamic interaction between vericiguat and nitroglycerin, co-administered in patients with chronic coronary syndromes, published in the Clinical Pharmacology and Therapeutics
- 15 Nov 2017 Results assessing safety presented at the 90th Annual Scientific Sessions of the American Heart Association.
- 23 Aug 2016 Status changed from recruiting to completed.